Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis

We describe 27 children and adolescents <18 years of age who received bedaquiline during treatment for multidrug-resistant tuberculosis. We report good treatment responses and no cessation attributable to adverse effects. Bedaquiline could be considered for use with this age group for multidrug-r...

Descripción completa

Detalles Bibliográficos
Autores principales: Achar, Jay, Hewison, Cathy, Cavalheiro, Ana P., Skrahina, Alena, Cajazeiro, Junia, Nargiza, Parpieva, Herboczek, Krzysztof, Rajabov, Assliddin S., Hughes, Jennifer, Ferlazzo, Gabriella, Seddon, James A., du Cros, Philipp
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2017
Materias:
Dispatch
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5621552/
https://www.ncbi.nlm.nih.gov/pubmed/28758889
http://dx.doi.org/10.3201/eid2310.170303
_version_ 1783267779523117056
author Achar, Jay
Hewison, Cathy
Cavalheiro, Ana P.
Skrahina, Alena
Cajazeiro, Junia
Nargiza, Parpieva
Herboczek, Krzysztof
Rajabov, Assliddin S.
Hughes, Jennifer
Ferlazzo, Gabriella
Seddon, James A.
du Cros, Philipp
author_facet Achar, Jay
Hewison, Cathy
Cavalheiro, Ana P.
Skrahina, Alena
Cajazeiro, Junia
Nargiza, Parpieva
Herboczek, Krzysztof
Rajabov, Assliddin S.
Hughes, Jennifer
Ferlazzo, Gabriella
Seddon, James A.
du Cros, Philipp
author_sort Achar, Jay
collection PubMed
description We describe 27 children and adolescents <18 years of age who received bedaquiline during treatment for multidrug-resistant tuberculosis. We report good treatment responses and no cessation attributable to adverse effects. Bedaquiline could be considered for use with this age group for multidrug-resistant tuberculosis when treatment options are limited.
format Online
Article
Text
id pubmed-5621552
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-56215522017-10-07 Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis Achar, Jay Hewison, Cathy Cavalheiro, Ana P. Skrahina, Alena Cajazeiro, Junia Nargiza, Parpieva Herboczek, Krzysztof Rajabov, Assliddin S. Hughes, Jennifer Ferlazzo, Gabriella Seddon, James A. du Cros, Philipp Emerg Infect Dis Dispatch We describe 27 children and adolescents <18 years of age who received bedaquiline during treatment for multidrug-resistant tuberculosis. We report good treatment responses and no cessation attributable to adverse effects. Bedaquiline could be considered for use with this age group for multidrug-resistant tuberculosis when treatment options are limited. Centers for Disease Control and Prevention 2017-10 /pmc/articles/PMC5621552/ /pubmed/28758889 http://dx.doi.org/10.3201/eid2310.170303 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Dispatch
Achar, Jay
Hewison, Cathy
Cavalheiro, Ana P.
Skrahina, Alena
Cajazeiro, Junia
Nargiza, Parpieva
Herboczek, Krzysztof
Rajabov, Assliddin S.
Hughes, Jennifer
Ferlazzo, Gabriella
Seddon, James A.
du Cros, Philipp
Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis
title Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis
title_full Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis
title_fullStr Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis
title_full_unstemmed Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis
title_short Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis
title_sort off-label use of bedaquiline in children and adolescents with multidrug-resistant tuberculosis
topic Dispatch
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5621552/
https://www.ncbi.nlm.nih.gov/pubmed/28758889
http://dx.doi.org/10.3201/eid2310.170303
work_keys_str_mv AT acharjay offlabeluseofbedaquilineinchildrenandadolescentswithmultidrugresistanttuberculosis
AT hewisoncathy offlabeluseofbedaquilineinchildrenandadolescentswithmultidrugresistanttuberculosis
AT cavalheiroanap offlabeluseofbedaquilineinchildrenandadolescentswithmultidrugresistanttuberculosis
AT skrahinaalena offlabeluseofbedaquilineinchildrenandadolescentswithmultidrugresistanttuberculosis
AT cajazeirojunia offlabeluseofbedaquilineinchildrenandadolescentswithmultidrugresistanttuberculosis
AT nargizaparpieva offlabeluseofbedaquilineinchildrenandadolescentswithmultidrugresistanttuberculosis
AT herboczekkrzysztof offlabeluseofbedaquilineinchildrenandadolescentswithmultidrugresistanttuberculosis
AT rajabovassliddins offlabeluseofbedaquilineinchildrenandadolescentswithmultidrugresistanttuberculosis
AT hughesjennifer offlabeluseofbedaquilineinchildrenandadolescentswithmultidrugresistanttuberculosis
AT ferlazzogabriella offlabeluseofbedaquilineinchildrenandadolescentswithmultidrugresistanttuberculosis
AT seddonjamesa offlabeluseofbedaquilineinchildrenandadolescentswithmultidrugresistanttuberculosis
AT ducrosphilipp offlabeluseofbedaquilineinchildrenandadolescentswithmultidrugresistanttuberculosis

Ejemplares similares